Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemotuzumab plus chemotherapy ± anlotinib as neoadjuvant therapy in locally advanced cervical cancer
ChiCTR2600116452Phase 4Not yet recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bemotuzumab in Cervical Cancer (CC), sponsored by Obstetrics and Gynecology Hospital of Fudan University. Primary endpoints: Pathological complete response (pCR) and Optimal Pathological Response (OPR, residual tumor <3 mm). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
bemotuzumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600116452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116452.